GNI Group Becomes Controlling Shareholder of Gyre Therapeutics with 69.1% Stake Post-Cullgen Merger
GYRE sits 22% above its 52-week low of $6.57.
Summary
GNI Group Ltd. and GNI USA, Inc. have become the controlling shareholders of Gyre Therapeutics, Inc., holding a combined 69.1% beneficial ownership following the completion of Gyre's $300 million all-stock acquisition of Cullgen Inc.
Key Events · Ownership and Investor Activity · GYRE
-
Controlling Stake Acquired
GNI Group Ltd. and GNI USA, Inc. now beneficially own 86,323,015 shares, representing 69.1% of Gyre Therapeutics' common stock.
-
Post-Merger Ownership
This significant ownership increase is a direct result of Gyre's $300 million all-stock acquisition of Cullgen Inc., which was completed on May 4, 2026.
-
Series B Preferred Stock
GNI received Series B Preferred Stock convertible into common shares, with conversion subject to shareholder approval at a meeting on June 10, 2026.
-
Lock-Up and Registration Rights
The filing details lock-up agreements for certain shares and a registration rights agreement, which could lead to future selling pressure from former Cullgen shareholders.
Analysis · GYRE · Life Sciences
This Schedule 13D/A details the significant shift in Gyre Therapeutics' ownership structure following its $300 million all-stock acquisition of Cullgen Inc. GNI Group, a former Cullgen shareholder, now beneficially owns 69.1% of Gyre's common stock, primarily through Series B Preferred Stock convertible into common shares. This establishes GNI as a controlling shareholder, which could have profound implications for corporate governance, strategic direction, and future capital allocation. The conversion of the Series B Preferred Stock is subject to shareholder approval, and the filing also notes lock-up agreements for certain shares and a registration rights agreement, indicating potential future selling pressure from former Cullgen holders. Investors should monitor the upcoming shareholder vote on the Series B Preferred Stock conversion and the long-term strategic alignment with the new controlling shareholder.
At the time of this filing, GYRE was trading at $8.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $779.8M. The 52-week trading range was $6.57 to $11.78. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.